St. Jude Claims 3-Point ICD Market Share Gain Since CRT Competition Began
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to limit prophylactic ICD coverage to patients with a QRS duration of over 0.12 seconds will increase demand for cardiac resynchronization therapy (CRT) ICDs at the expense of conventional implantable defibrillators, St. Jude Medical maintains
You may also be interested in...
St. Jude Expects Epic HF CRT Approval By May 2004 NASPE/HRS Meeting
St. Jude Medical is lowering average selling prices for its U.S. ICDs and pacemakers by roughly 5% to counter Guidant and Medtronic's strategy of "bundling" cardiac resynchronization therapy defibrillators (CRT-D) with traditional ICDs and pacemakers
St. Jude Expects Epic HF CRT Approval By May 2004 NASPE/HRS Meeting
St. Jude Medical is lowering average selling prices for its U.S. ICDs and pacemakers by roughly 5% to counter Guidant and Medtronic's strategy of "bundling" cardiac resynchronization therapy defibrillators (CRT-D) with traditional ICDs and pacemakers
Wireless CareLink, “Virtual” Cath Labs Bring IT Emphasis To Medtronic CRT
Medtronic plans to release two new heart failure devices in the next 12 months, both featuring the firm's CareLink remote patient management network